相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?
Raghava Reddy et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
Pamela U. Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Inhibitory Effects of Antivascular Endothelial Growth Factor Strategies in Experimental Dopamine-Resistant Prolactinomas
Guillermina Maria Luque et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways
Erika Peverelli et al.
CANCER LETTERS (2010)
Non-functioning pituitary adenomas
Yona Greenman et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1
Nina Korsisaari et al.
CLINICAL CANCER RESEARCH (2008)
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
Tullio Florio et al.
ENDOCRINE-RELATED CANCER (2008)
Medical therapy for clinically non-functioning pituitary adenomas
Annamaria Colao et al.
ENDOCRINE-RELATED CANCER (2008)
What is the natural history of nonoperated nonfunctioning pituitary adenomas?
N. Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2007)
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2007)
Neurological manifestations in Fabry's disease
Anette T Moller et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours
Chiara Onofri et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas
M Niveiro et al.
HUMAN PATHOLOGY (2005)
Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth
Y Greenman et al.
CLINICAL ENDOCRINOLOGY (2005)
Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice
C Cristina et al.
ENDOCRINOLOGY (2005)
Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in pituitary adenomas
K Kim et al.
ENDOCRINE PATHOLOGY (2005)
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas
P Park et al.
NEUROSURGERY (2004)
Evidence for differential effects of selective somatostatin receptor subtype agonists on α-subunit and chromogranin A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro
MC Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas
C Onofri et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2004)
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: Effects on cell viability, GH, and PRL secretion
MC Zatelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth
Y Greenman et al.
CLINICAL ENDOCRINOLOGY (2003)
Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors
CJ McCabe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary
S Vidal et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2002)
Dopamine as a prolactin (PRL) inhibitor
N Ben-Jonathan et al.
ENDOCRINE REVIEWS (2001)
Somatostatin receptor-specific analogs: Effects on cell proliferation and growth hormone secretion in human somatotroph tumors
DC Danila et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor
S Basu et al.
NATURE MEDICINE (2001)
Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen
AL Ochoa et al.
JOURNAL OF ENDOCRINOLOGY (2000)
分享论文
